Appraising screening, making risk in/visible. The medical debate over Non‐Rare Thrombophilia (NRT) testing before prescribing the pill (20 mai 2022 – 11h)

Appraising screening, making risk in/visible. The medical debate over Non‐Rare Thrombophilia (NRT) testing before prescribing the pill (20 mai 2022 – 11h)

Appraising screening, making risk in/visible. The medical debate over Non‐Rare Thrombophilia (NRT) testing before prescribing the pill (20 mai 2022 – 11h)

Aucun commentaire sur Appraising screening, making risk in/visible. The medical debate over Non‐Rare Thrombophilia (NRT) testing before prescribing the pill (20 mai 2022 – 11h)

Dans le cadre des journées santé du LIRAESorganisées par Maïva Ropaul & Jonathan SicsicCatherine BOURGAINDirectrice du CERMES3, UNIVERSITE DE PARIS, INSERM, EHESS, CNRS & Maura TURRINIIPP, CSIC, Madrid, Spainprésenteront une étude intitulée : « Appraising screening, making risk in/visible. The medical debate over Non‐Rare Thrombophilia (NRT) testing before prescribing the pill »le vendredi 20 mai 2022 à 11h.


Abstract

Non-rare thrombophilia (NRT) are hereditary predispositions to thromboembolism, the most severe side effect of combined hormonalcontraception. In the mid-1990s, theidentification of NRT stirred up acontroversy over the possibility of investigating these genetic variants inwomen wishing to use contraception. Through a review of literature, thisarticle reconstructs the debate over whether and how this genetic test shouldbe prescribed as a way to reconfigure the risk visibility on pharmacologicalcontraception. The mainarguments identified concern the epidemiological,social, economic and clinical aspects of the test. In a context where theoverall thrombotic risk for hormonal contraception is largelyinvisible, thegenetic tests turn to embody the thrombotic risk itself. Those who opt forselective screening argue that a better estimation of risk implies a testprescription embed in aglobal medical assessment of women’s individual risk.To advocates of universal or ‘extended’ screening, the tests are valuable toolsto inform women on the thrombotic risk and, assuch, appraised as a moral/legalobligation, whatever their predictive power. Risk visibility thus appears as aninsightful concept to analyse a complex setting associating clinical,political, social and cultural considerations that touches upon medical power,women’s responsibility and drug safety.

Ce séminaire aura lieu =
en présentiel au LIRAES
Université de Paris
Campus Saint Germain
45 rue des Saints Pères – 75006 PARIS
8ème étage – Bibliothèque de l’IDS
&
sur Zoom 
Voici le lien pour participer à la réunion en visioconférence : https://u-paris.zoom.us/j/83087531091?pwd=TE96bHRFRGF6SThpODA5bFhkbWwzdz09

Ces séminaires mensuels sont l’occasion pour les chercheurs en économie (de la santé) de présenter leurs travaux de recherche en cours.

La durée de chaque séminaire est d’une heure environ.

ADRESSE
45 rue des Saints Pères - 75006 Paris
TELEPHONE & MAIL
01 42 86 20 71 - liraes.deg@u-paris.fr


logo_liraes

Back to Top